JACKSONVILLE, Fla., Jan. 24, 2017 /PRNewswire/ -- TapImmune, Inc. (NASDAQ: TPIV), a clinical-stage
immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics for the treatment
of cancer and metastatic disease, today announced that Memorial Sloan Kettering Cancer Center (MSKCC) successfully completed the
first safety cohort in its Phase 2 ovarian cancer study. The study is designed to examine the efficacy of the TapImmune lead
investigational product candidate, TPIV 200, in combination with AstraZeneca's investigational checkpoint inhibitor,
durvalumab.
The Phase 2 ovarian cancer study is sponsored by MKSCC under the leadership of Dr. Jason
Konner. This clinical milestone allows MSKCC to increase the number of patients that can be enrolled and will subsequently
increase the study's enrollment rate. Patients in this study are resistant to platinum chemotherapy and have few treatment
options. Since TPIV 200 and durvalumab have not been used before in combination, the protocol required the start of the study to
proceed cautiously for the first four patients. There have been no safety issues to date, and the enrollment is now allowed to
proceed at a faster rate.
"This study and the TapImmune-sponsored Phase 2 study in triple negative breast cancer study represent the company's progress
in clinical development of its lead product, TPIV 200," said Glynn Wilson, Chairman and CEO of
TapImmune, Inc. "We also recently announced the opening of our second ovarian cancer study with FDA Fast Track designation in
platinum-sensitive patients. As we have previously stated, TapImmune has Fast Track designation for TPIV 200 as
maintenance therapy in subjects with platinum-sensitive advanced ovarian cancer who achieved stable disease or partial response
following completion of standard of care chemotherapy."
About TapImmune, Inc.
TapImmune, Inc. is an immuno-oncology company specializing in the development of innovative technologies for the
treatment of cancer, including metastasis, and infectious disease. The company's peptide or nucleic acid-based
immunotherapeutics, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a
patients' killer T-cells, helper T-cells and to restore or further augment antigen presentation by using proprietary nucleic
acid-based expression systems. The company's technologies may be used as stand-alone medications or in combination with current
treatment modalities.
Please visit the company's website at www.tapimmune.com
for more details.
Forward-Looking Statement Disclaimer
This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995.
Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any
other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters,
are "forward-looking statements". Forward-looking statements are by their nature subject to risks, uncertainties and other
factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and
factors include, but are not limited to the risks set forth in the Company's most recent Form 10-K, 10-Q and other SEC filings
which are available through EDGAR at www.sec.gov. The Company assumes no
obligation to update the forward-looking statements.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/tapimmune-announces-progress-in-its-phase-2-ovarian-cancer-clinical-trial-300395274.html
SOURCE TapImmune, Inc.